These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 39164224)

  • 1. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
    Pascual-Pasto G; McIntyre B; Hines MG; Giudice AM; Garcia-Gerique L; Hoffmann J; Mishra P; Matlaga S; Lombardi S; Shraim R; Schürch PM; Yarmarkovich M; Hofmann TJ; Alikarami F; Martinez D; Tsang M; Gil-de-Gómez L; Spear TT; Bernt KM; Wolpaw AJ; Dimitrov DS; Li W; Bosse KR
    Nat Commun; 2024 Aug; 15(1):7141. PubMed ID: 39164224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
    Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
    Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
    Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
    Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
    Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
    Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
    Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
    Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
    Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
    Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.
    Pascual-Pasto G; McIntyre B; Giudice AM; Alikarami F; Morrissey A; Matlaga S; Hofmann TJ; Burgueño V; Harvey K; Martinez D; Shah AC; Foster JB; Pogoriler J; Eagle RC; Carcaboso AM; Shields CL; Leahey AM; Bosse KR
    Clin Cancer Res; 2024 Aug; 30(16):3578-3591. PubMed ID: 38864848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
    Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
    Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
    Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
    Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
    Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D'Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
    Clin Cancer Res; 2024 Jun; 30(11):2545-2557. PubMed ID: 38551501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
    Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
    Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.